Yalu Liu, International Director, Transmural Biotech

Regarding breast cancer, Transmural Biotech’s algorithm detects—at its current stage of our development, —23 percent more cases than what a pathologist can warn with conventional methods. Further, the company’s products can also be used to detect melanoma and dermatological diseases, where the tests can help exceed the productivity of specialists by 57 percent.

Lorente mentions that the small number of competitors in the market for making predictive algorithms based on the application of AI to medical images is astonishing. “Although there is an increasing proliferation of AI to study health data, the genetic material of pathogens, and to personalize medical treatments, the images frontier has not been tapped much by the technology,” he adds. To this end, Transmural Biotech is looking for startups to join the small group of consolidated companies like them. “We believe that the biggest movement will be when the large international pharmaceutical laboratories and industries are going to get decidedly involved (through alliances, purchases, or own developments) in AI applied to images,” says Lorente.

For the future, Transmural Biotech is working to diagnose many more complicated illnesses, as Lorente informs, “I work to find alliances that provide us with quality images that are medically well informed. We are looking forward to finding marketing agreements in geographic areas and working with manufacturers of medical imaging equipment. I work to be profitable to our shareholders and offer creative and satisfying employment for our collaborators. This year will establish us as one of the best global company that develops AI-based algorithms that diagnoses conditions from medical images.”